2-溴-5-氯-4-甲基苯胺 | 102170-52-5

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-溴-5-氯-4-甲基苯胺
• 英文名称: 2-bromo-5-chloro-4-methylaniline
• 英文别名: 2-bromo-5-chloro-4-methyl-aniline；2-Brom-5-chlor-4-methyl-anilin；2-bromo-5-chloro-4-methylphenylamine
• CAS: 102170-52-5
• 化学式: C₇H₇BrClN
• mdl: MFCD00806533
• 分子量: 220.496
• InChiKey: ULCBEYQOSOVMMA-UHFFFAOYSA-N

物化性质

• 熔点：
  90 °C
• 沸点：
  281.3±35.0 °C(Predicted)
• 密度：
  1.619±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2921430090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温下应存放在干燥密封的环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Bromo-5-chloro-4-methylaniline
Synonyms: 4-Amino-5-bromo-2-chlorotoluene

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-5-chloro-4-methylaniline
CAS number: 102170-52-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H7BrClN
Molecular weight: 220.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-5-氯-4-甲基苯胺 在 三氟化硼乙醚 、 四乙基氯化铵 、 亚硝酸特丁酯 作用下， 以 乙腈 为溶剂， 反应 1.17h， 以92%的产率得到1-溴-2,4-二氯-5-甲基苯
  参考文献：
  名称：

  固定化Cu I / Cu II基催化剂的高效Sandmeyer反应

  摘要：

  对于在Silochrom载体上掺入离子液体的Cu基催化剂，已经揭示了Sandmeyer反应的高效实施方案。活性最高的催化剂（TOF = = 4000–8000 h-1）包含相当数量的亚铜和氯化铜阴离子。报道的方法允许以一锅模式对苯胺进行反应。

  DOI：

  10.1016/j.mencom.2018.05.010
• 作为产物：
  描述：

  3-氟-4-甲基乙酰苯胺 在 sodium hydroxide 、 溴 、 溶剂黄146 作用下， 生成 2-溴-5-氯-4-甲基苯胺
  参考文献：
  名称：

  Synthesis of Ring-Substituted N-Phenylglycines, Their Nitriles and Amides

  摘要：

  DOI：

  10.1021/jo01360a028

文献信息

• Anti-quinazoline compounds
  申请人：Cancer Research Technology Limited

  公开号：US06699861B1

  公开（公告）日：2004-03-02

  Dihydroquinazoline derivatives of the formula where R3 is —(CH2)p—A where p is from 1 to 4 and A is a 5- or 6-membered N-containing heterocyclic ring attached via the N atom or A is —NA′A″ wherein A′ and A″ are the same or different and are each a C1-C4 alkyl group or their pharmaceutically acceptable salts possessing anti-cancer activity.

  Dihydroquinazoline衍生物的化学式中，其中R3为—(CH2)p—A，其中p为1至4，A是通过N原子连接的含有5个或6个成员的N-含氮杂环环，或者A是—NA′A″，其中A′和A″相同或不同，分别为C1-C4烷基或其药学上可接受的盐，具有抗癌活性。
• Copper-Catalyzed Tandem Cross-Coupling/[2 + 2] Cycloaddition of 1,6-Allenynes with Diazo Compounds to 3-Azabicyclo[5.2.0] Ring Systems
  作者：Min He、Nuan Chen、Ting Zhou、Qing Li、Hongguang Li、Ming Lang、Jian Wang、Shiyong Peng

  DOI：10.1021/acs.orglett.9b03727

  日期：2019.12.6

  An unprecedented copper-catalyzed tandem cross-coupling/[2 + 2] cycloaddition of 1,6-allenynes with diazo compounds was reported, chemo- and regioselectively providing 3-azabicyclo[5.2.0] frameworks in moderate to excellent yields under mild reaction conditions. Moreover, the products readily convert to highly functionalized quinolines via oxidative radical rearrangement.

  据报道，空前的铜催化串联交叉偶联/ [2 + 2]与重氮化合物进行1,6-炔炔的环加成反应，在温和的反应下，化学和区域选择性地以中等至优异的产率提供了3-氮杂双环[5.2.0]骨架。情况。而且，产物容易通过氧化自由基重排转化为高度官能化的喹啉。
• Synthesis of substituted <i>Z</i>-styrenes by Hiyama-type coupling of oxasilacycloalkenes: application to the synthesis of a 1-benzoxocane
  作者：James R Vyvyan、Courtney A Engles、Scott L Bray、Erik D Wold、Christopher L Porter、Mikhail O Konev

  DOI：10.3762/bjoc.13.209

  日期：——

  Several Hiyama cross-coupling reactions of oxasilacycloalkenes and aryl iodides are described that produce trisubstituted Z-styrenes in moderate to excellent yields. Both electron-rich and electron-poor aryl iodides are tolerated in the cross-coupling reaction. The oxasilacycloalkene coupling partners were prepared by ruthenium-catalyzed intramolecular anti-hydrosilylation of alkynols. One of the cross-coupling products was converted to a 1-benzoxocane, albeit in low yield, using an intramolecular Buchwald–Hartwig etherification. The cyclic ether produced contains the carbon skeleton of heliannuol A.

  描述了几种氧硅环烯烃和芳基碘在Hiyama交叉偶联反应中的反应，产生了产率在中等到优良之间的三取代Z-苯乙烯。在交叉偶联反应中，既可容忍富电子又可容忍贫电子的芳基碘。氧硅环烯烃偶联配体是通过钌催化的炔醇分子内抗氢硅化反应制备的。其中一个偶联产物通过分子内Buchwald–Hartwig醚化反应转化为1-苯并噁咯烷，尽管产率较低。所产生的环状醚含有heliannuol A的碳骨架。
• [EN] ANTI-CANCER DIHYDROQUINAZOLINE DERIVATIVES<br/>[FR] DERIVES DE DIHYDROQUINAZOLINE ANTICANCEREUX
  申请人：CANCER RES CAMPAIGN TECH

  公开号：WO2000050417A1

  公开（公告）日：2000-08-31

  A dihydroquinazoline derivative of formula (I), or a pharmaceutically acceptable salt thereof, wherein: either R1 and R1' together form an oxo group and R2 is hydrogen, C1-C4 alkyl, -(C1-C4 alkyl)-COB, -(C1-C4 alkyl)-CO-(C1-C4 alkyl)-B, -(C1-C4 alkyl)-CO2-(C1-C4 alkyl)-B, -(C1-C4 alkyl)-CO2-(C2-C4 alkenyl)-B or -(C1-C4 alkyl)-CONH-(C1-C4 alkyl)-B wherein B is -CO2H, hydroxy, C1-C4 alkoxy, amino, (C1-C4 alkyl)amino, di(C1-C4 alkyl)amino or a 5- or 6-membered heterocyclic group, or R1' and R2 together form a bond and R1 is -S-(C1-C4 alkyl), -NHR' or -NHCOR' wherein R' is aryl or C1-C4 alkyl; R3 is -(CH2)p-A wherein p is from 1 to 4 and A is a 5- or 6-membered N-containing heterocyclic ring attached via the N atom or A is -NA'A' wherein A' and A' are the same or different and are each a C1-C4 alkyl group; either R4 is hydrogen, oxo or C1-C4 alkyl and R5 is hydrogen, C1-C4 alkyl or halogen, or R4 and R5, together with the carbon atoms to which they are attached, form a 5- or 6-membered carbocyclic ring; X1 is -O-, -S- or -NR'- wherein R' is hydrogen, C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl; Y is a divalent aryl or heteroaryl group; R6 is hydrogen, oxo or C1-C4 alkyl; X2 is -O-, -S- or -NR'- wherein R' is as defined above; m is from 1 to 4; and R7 is pyridyl, pyrimidyl, imidazolyl, triazolyl, -(C1-C4 alkyl)-imidazolyl, or -(C1-C4 alkyl)-triazolyl.

  公式（I）的二氢喹唑啉衍生物，或其药学上可接受的盐，其中：R1和R1'要么一起形成一个氧代基，且R2为氢、C1-C4烷基、-(C1-C4烷基)-COB、-(C1-C4烷基)-CO-(C1-C4烷基)-B、-(C1-C4烷基)-CO2-(C1-C4烷基)-B、-(C1-C4烷基)-CO2-(C2-C4烯基)-B或-(C1-C4烷基)-CONH-(C1-C4烷基)-B，其中B为-CO2H、羟基、C1-C4烷氧基、氨基、(C1-C4烷基)氨基、二(C1-C4烷基)氨基或5-或6-成员杂环基；或者R1'和R2一起形成一个键，且R1为-S-(C1-C4烷基)、-NHR'或-NHCOR'，其中R'为芳基或C1-C4烷基；R3为-(CH2)p-A，其中p为1至4，A为通过N原子连接的5-或6-成员含N杂环环或A为-NA'A'，其中A'和A'相同或不同，且均为C1-C4烷基；要么R4为氢、氧代基或C1-C4烷基，且R5为氢、C1-C4烷基或卤素，或者R4和R5与它们所连接的碳原子一起形成一个5-或6-成员的碳环；X1为-O-、-S-或-NR'-，其中R'为氢、C1-C4烷基、C2-C4烯基或C2-C4炔基；Y为二价芳基或杂芳基基团；R6为氢、氧代基或C1-C4烷基；X2为-O-、-S-或-NR'-，其中R'如上所定义；m为1至4；R7为吡啶基、嘧啶基、咪唑基、三唑基、-(C1-C4烷基)-咪唑基或-(C1-C4烷基)-三唑基。
• Compounds As Ccri Antagonists
  申请人：Heng Richard

  公开号：US20070196270A1

  公开（公告）日：2007-08-23

  A compound of formula I, or a pharmaceutically acceptable salt or ester thereof, wherein the symbols have meaning as defined, which are antagonists of CCR-1 and which find use pharmaceutically for treatment of diseases and conditions in which CCR-1 is implicated, e.g. inflammatory diseases.

  化合物I的公式，或其药学上可接受的盐或酯，其中符号的含义如定义的那样，它们是CCR-1的拮抗剂，并且在药学上用于治疗与CCR-1有关的疾病和症状，例如炎症性疾病。